Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection

Highlights • Mefloquine and its oxazolidine derivative 1E were active in a murine model of tuberculosis (TB). • Mefloquine and 1E were active after oral administration in infected mice. • 1E did not interact with isoniazid, rifampicin, ethambutol, moxifloxacin or streptomycin. • Combination of meflo...

Full description

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2016-08, Vol.48 (2), p.203-207
Main Authors: Rodrigues-Junior, Valnês S, Villela, Anne D, Gonçalves, Raoni S.B, Abbadi, Bruno Lopes, Trindade, Rogério Valim, López-Gavín, Alexandre, Tudó, Griselda, González-Martín, Julian, Basso, Luiz Augusto, de Souza, Marcus V.N, Campos, Maria Martha, Santos, Diógenes Santiago
Format: Article
Language:English
Subjects:
Animals
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Bacterial Load
Combination
Disease Models, Animal
Drug Interactions
Drug Repositioning
Infectious Disease
Male
Mefloquine
Mefloquine - pharmacology
Mefloquine - therapeutic use
Mice
Microbial Sensitivity Tests
Murine model
Mycobacterium tuberculosis - drug effects
Oxazoles - pharmacology
Oxazoles - therapeutic use
Quinolone-resistant strains
Tuberculosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - microbiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Mefloquine and its oxazolidine derivative 1E were active in a murine model of tuberculosis (TB). • Mefloquine and 1E were active after oral administration in infected mice. • 1E did not interact with isoniazid, rifampicin, ethambutol, moxifloxacin or streptomycin. • Combination of mefloquine with five anti-TB drugs did not result in antagonism. • Mefloquine and 1E were active against quinolone-resistant clinical isolates.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2016.04.029